CABALETTA BIO INC (CABA)
US12674W1099 - Common Stock
Overall CABA gets a fundamental rating of 2 out of 10. We evaluated CABA against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CABA as it has an excellent financial health rating, but there are worries on the profitability. CABA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CABA has reported negative net income.
CABA had a negative operating cash flow in the past year.
In the past 5 years CABA always reported negative net income.
CABA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -50.96%, CABA is in line with its industry, outperforming 47.69% of the companies in the same industry.
CABA has a better Return On Equity (-59.78%) than 61.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.96% | ||
| ROE | -59.78% | ||
| ROIC | N/A |
ROA(3y)-36.2%
ROA(5y)-30.68%
ROE(3y)-39.53%
ROE(5y)-33.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CABA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, CABA has more shares outstanding
CABA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CABA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CABA has an Altman-Z score of -0.64. This is a bad value and indicates that CABA is not financially healthy and even has some risk of bankruptcy.
CABA's Altman-Z score of -0.64 is fine compared to the rest of the industry. CABA outperforms 60.68% of its industry peers.
There is no outstanding debt for CABA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.64 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CABA has a Current Ratio of 8.11. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
CABA's Current ratio of 8.11 is fine compared to the rest of the industry. CABA outperforms 73.31% of its industry peers.
A Quick Ratio of 8.11 indicates that CABA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.11, CABA is in the better half of the industry, outperforming 73.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.11 | ||
| Quick Ratio | 8.11 |
3. Growth
3.1 Past
CABA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.73%.
EPS 1Y (TTM)-25.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
CABA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-42.98%
EPS Next 2Y-27.17%
EPS Next 3Y-17.91%
EPS Next 5Y0.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CABA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CABA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CABA's earnings are expected to decrease with -17.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.17%
EPS Next 3Y-17.91%
5. Dividend
5.1 Amount
CABA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CABALETTA BIO INC
NASDAQ:CABA (12/27/2024, 10:23:02 AM)
2.35
-0.14 (-5.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners106.87%
Inst Owner Change-5.17%
Ins Owners3.1%
Ins Owner Change0%
Market Cap114.87M
Analysts86.67
Price Target22.54 (859.15%)
Short Float %9.51%
Short Ratio1.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.09%
Min EPS beat(2)-1.96%
Max EPS beat(2)-0.22%
EPS beat(4)0
Avg EPS beat(4)-5.56%
Min EPS beat(4)-14.93%
Max EPS beat(4)-0.22%
EPS beat(8)3
Avg EPS beat(8)0.15%
EPS beat(12)7
Avg EPS beat(12)6.75%
EPS beat(16)10
Avg EPS beat(16)6.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.49%
PT rev (3m)-9.18%
EPS NQ rev (1m)-4.04%
EPS NQ rev (3m)-17.94%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)-2.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.66 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.15
EYN/A
EPS(NY)-2.67
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0
BVpS3.56
TBVpS3.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.96% | ||
| ROE | -59.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.2%
ROA(5y)-30.68%
ROE(3y)-39.53%
ROE(5y)-33.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.06% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.11 | ||
| Quick Ratio | 8.11 | ||
| Altman-Z | -0.64 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)138.69%
Cap/Depr(5y)257.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.57%
EPS Next Y-42.98%
EPS Next 2Y-27.17%
EPS Next 3Y-17.91%
EPS Next 5Y0.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-68.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.5%
EBIT Next 3Y-37.89%
EBIT Next 5YN/A
FCF growth 1Y-77.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.15%
OCF growth 3YN/A
OCF growth 5YN/A